Anti-RSV F protein (Nirsevimab)
Produktgrößen
1 mg
£552,00
12-8488-1MG
50 mg
£4683,00
12-8488-50MG
Über dieses Produkt
- SKU:
- 12-8488
- Zusätzliche Namen:
- Human respiratory syncytial virus (hRSV); Respiratory syncytial virus (RSV)
- Anwendung:
- ELISA
- translate.label.attr.clone:
- MEDI8897
- Klonalität:
- Monoclonal
- Weitere Details:
- Specificity: Nirsevimab binds the F1 and F2 subunits of the prefusion RSV F protein at a highly conserved epitope in antigenic site ?.Antigen Distribution: F protein is found in RSV virion membranes in either an inactive prefusion conformation or an active postfusion conformation.Background: Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory tract infection and hospitalization in infants1. RSV F protein is a type I integral membrane protein essential for viral membrane fusion that is highly conserved among isolates of RSV A and B subgroups2. F protein has been investigated as a target for neutralizing antibodies; small molecular antiviral drug development; as a vaccine antigen; and as an antibody target for passive prophylaxis. F protein is synthesized as an inactive; palmitoylated precursor (F0) and is decorated with N-linked glycans2. Three F0 monomers form a trimer and become activated by a furin-like host protease as they pass through the Golgi. The protease cleaves twice; generating three polypeptides: F2 and F1; which are covalently linked; and pep27; an intervening peptide that dissociates after cleavage. When functional F protein trimer in the virion membrane is triggered; it undergoes a major conformational change from a prefusion to postfusion form. Approximately 25% of isolate specific variability for F protein is found within an antigenic site at the apex of the prefusion trimer (antigenic site ?); composed of an ?-helix from F1 (aa 196?210) and a strand from F2 (aa 62?69). Nirsevimab is a long-acting; neutralizing recombinant human monoclonal antibody that binds the F1 and F2 subunits of F protein at a highly conserved epitope in antigenic site ? and locks the RSV F protein in the prefusion conformation; blocking viral entry into the host cell1; 3; 4. In vitro; nirsevimab binds to immobilized human Fc?Rs (Fc?RI; Fc?RIIA; Fc?RIIB and Fc?RIII)3. Protection from infection is thought to be dependent on neutralization activity rather than Fc-mediated effector function based on data from a cotton rat model of RSV infection3. Nirsevimab has been modified with a triple amino acid substitution (YTE) in the Fc region to extend the serum half-life3. Nirsevimab originates from the D25 antibody developed by AIMM Therapeutics and was jointly developed and commercialized by AstraZeneca and Sanofi for the prevention of RSV infection in neonates and infants.
- Host:
- Human
- Isotyp:
- Human IgG1k
- Aufreinigung:
- Purity :>=95% by SDS PagePreparation : Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a mult
- Reaktivitäten:
- Human
- Versandbedingungen:
- Blue Ice
- Lagerbedingungen:
- Functional grade preclinical antibodies may be stored sterile as received at 2-8[o]C for up to one month. For longer term storage; aseptically aliquot in working volumes without diluting and store at
- Hersteller:
- Abeomics
- Typ:
- Antibodies:Monoclonal Antibody
- Datenblatt des Herstellers:download_pdf.php